{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T19:36:43Z","timestamp":1778873803998,"version":"3.51.4"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC0870600"],"award-info":[{"award-number":["2022YFC0870600"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012401","name":"Beijing Science and Technology Planning Project","doi-asserted-by":"publisher","award":["Z221100007922012"],"award-info":[{"award-number":["Z221100007922012"]}],"id":[{"id":"10.13039\/501100012401","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ebiom.2022.104386","type":"journal-article","created":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T03:22:45Z","timestamp":1670210565000},"page":"104386","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Safety and immunogenicity of a bivalent SARS-CoV-2 protein\u00a0booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: a randomized, double-blind, placebo-controlled phase 1\/2 clinical trial"],"prefix":"10.1016","volume":"87","author":[{"given":"Suad","family":"Hannawi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"Saf Eldin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1621-0777","authenticated-orcid":false,"given":"Alaa","family":"Abuquta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Alamadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sally A.","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aala","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongfang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lixin","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangzhi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2022.104386_bib2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41541-022-00459-z","article-title":"Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant","volume":"7","author":"Ari\u00ebn","year":"2022","journal-title":"NPJ Vaccines"},{"key":"10.1016\/j.ebiom.2022.104386_bib3","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1056\/NEJMc2119912","article-title":"SARS-CoV-2 omicron variant neutralization after mRNA-1273 booster vaccination","volume":"386","author":"Pajon","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ebiom.2022.104386_bib4","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1056\/NEJMc2206711","article-title":"Immunogenicity and safety of beta-adjuvanted recombinant booster vaccine","volume":"387","author":"Launay","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ebiom.2022.104386_bib5","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa2208343","article-title":"A\u00a0bivalent omicron-containing booster vaccine against Covid-19","volume":"387","author":"Chalkias","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ebiom.2022.104386_bib6","doi-asserted-by":"crossref","first-page":"100679","DOI":"10.1016\/j.xcrm.2022.100679","article-title":"Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant","volume":"3","author":"Lyke","year":"2022","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.ebiom.2022.104386_bib7","first-page":"795","article-title":"Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK: three month analyses of the COV-BOOST trial","volume":"84","author":"Liu","year":"2022","journal-title":"J\u00a0Infect"},{"key":"10.1016\/j.ebiom.2022.104386_bib8","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1038\/s41467-022-30884-6","article-title":"Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine","volume":"13","author":"Patalon","year":"2022","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.ebiom.2022.104386_bib10","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1038\/s41591-022-02031-7","article-title":"Safety, immunogenicity and antibody persistence of a bivalent beta-containing booster vaccine against COVID-19: a phase 2\/3 trial","volume":"28","author":"Chalkias","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2022.104386_bib11","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1038\/s41467-022-31379-0","article-title":"Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial","volume":"13","author":"Kaabi","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ebiom.2022.104386_bib12","first-page":"4164","article-title":"A\u00a0heterologous V-01 or variant-matched bivalent V-01D-351 booster following primary series of inactivated vaccine enhances the neutralizing capacity against SARS-CoV-2 delta and omicron strains","volume":"11","author":"Zhang","year":"2022","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.ebiom.2022.104386_bib13","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.virol.2022.09.003","article-title":"Development of a thermostable SARS-CoV-2 variant-based bivalent protein vaccine with cross-neutralizing potency against Omicron subvariants","volume":"576","author":"Wang","year":"2022","journal-title":"Virology"},{"key":"10.1016\/j.ebiom.2022.104386_bib14","doi-asserted-by":"crossref","first-page":"702","DOI":"10.3390\/vaccines10050702","article-title":"A\u00a0bivalent COVID-19 vaccine based on\u00a0alpha and beta variants elicits potent and broad immune responses in mice against SARS-CoV-2 variants","volume":"10","author":"Wang","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ebiom.2022.104386_bib15","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.jmb.2004.09.079","article-title":"Foldon, the natural trimerization domain of T4 fibritin, dissociates into a monomeric A-state form containing a stable beta-hairpin: atomic details of trimer dissociation and local beta-hairpin stability from residual dipolar couplings","volume":"344","author":"Meier","year":"2004","journal-title":"J\u00a0Mol Biol"},{"key":"10.1016\/j.ebiom.2022.104386_bib17","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1515\/cclm-2021-0023","article-title":"Evaluation of the automated LIAISON\u00ae SARS-CoV-2 TrimericS IgG assay for the detection of circulating antibodies","volume":"59","author":"Bonelli","year":"2021","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.ebiom.2022.104386_bib19","first-page":"150","article-title":"Immune response of booster doses of BBIBP-CORV vaccines against the variants of concern of SARS-CoV-2","author":"Mahmoud","year":"2022","journal-title":"J\u00a0Clin Virol"},{"key":"10.1016\/j.ebiom.2022.104386_bib20","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.ijid.2021.09.073","article-title":"Performance of the T-SPOT\u24c7.COVID test for detecting SARS-CoV-2-responsive T cells","volume":"113","author":"Kruse","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ebiom.2022.104386_bib21","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1473-3099(21)00681-2","article-title":"Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomized, placebo-controlled phase 2 clinical trials","volume":"22","author":"Zeng","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ebiom.2022.104386_bib22","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1038\/s41467-022-29477-0","article-title":"Neutralizing activity of BBIBP-CorV vaccine-elicited sera against beta, delta and other SARS-CoV-2 variants of concern","volume":"13","author":"Yu","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.ebiom.2022.104386_bib23","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","article-title":"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey","volume":"398","author":"Tanriover","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2022.104386_bib24","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2022.104386_bib25","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0140-6736(22)00094-0","article-title":"Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study","volume":"399","author":"Costa Clemens","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2022.104386_bib26","doi-asserted-by":"crossref","first-page":"948014","DOI":"10.3389\/fcimb.2022.948014","article-title":"Neutralizing activity against SARS-CoV-2 delta and omicron variants following a third BNT162b2 booster dose according to three homologous or heterologous COVID-19 vaccination schedules","volume":"12","author":"Choi","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.ebiom.2022.104386_bib27","author":"Leung"},{"issue":"4","key":"10.1016\/j.ebiom.2022.104386_bib28","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.chom.2022.02.015","article-title":"Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2","volume":"30","author":"Xia","year":"2022","journal-title":"Cell Host Microbe"},{"issue":"7","key":"10.1016\/j.ebiom.2022.104386_bib29","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.3390\/vaccines10071049","article-title":"Percentage of asymptomatic infections among SARS-CoV-2 omicron variant-positive individuals: a systematic review and meta-analysis","volume":"10","author":"Shang","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.ebiom.2022.104386_bib30","doi-asserted-by":"crossref","first-page":"362","DOI":"10.7326\/M20-3012","article-title":"Prevalence of asymptomatic SARS-CoV-2 infection. A narrative review","volume":"173","author":"Oran","year":"2020","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.ebiom.2022.104386_bib31","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/s41591-022-01704-7","article-title":"Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination","volume":"28","author":"Cheng","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.ebiom.2022.104386_bib32","article-title":"Booster of mRNA-1273 strengthens SARS-CoV-2 omicron neutralization","author":"Doria-Rose","year":"2021","journal-title":"medRxiv"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422005680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396422005680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:21:00Z","timestamp":1762456860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396422005680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":28,"alternative-id":["S2352396422005680"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.104386","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of a bivalent SARS-CoV-2 protein\u00a0booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: a randomized, double-blind, placebo-controlled phase 1\/2 clinical trial","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2022.104386","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104386"}}